Novo Nordisk JPMorgan

News

Novo Nordisk, Wegovy

Novo Nordisk Stock Jumps Despite Full-Year Outlook Cut

U.S.-listed shares of Novo Nordisk are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered its full-year outlook.

Reuters on MSN · 4d

Novo Nordisk hopes to see US Wegovy sales recover soon

Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound copycats is enforced this month, its CEO said on Wednesday after the company cut its 2025 forecasts.

CNBC on MSN · 4d

It's going to be 'put up or shut up' for Novo Nordisk's Wegovy this summer: Barclays' Emily Field

Emily Field, Barclacys head of European pharmaceuticals equity research, joins 'Squawk Box' to discuss Novo Nordisk's quarterly earnings results, impact of copycat compounded drugs on Wegovy sales, state of the obesity drug competition,

9don MSN

Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

3don MSN

Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs

Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster ...

Can Ozempic Hype Keep Novo Nordisk Stock (NVO) Strong after Q1?

Detailed price information for JP Morgan Chase & Company (JPM-N) from The Globe and Mail including charting and trades.

Eli Lilly stock sell-off was 'overreaction': Analysts

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...

NBC Chicago4d

Healthy Returns: Novo Nordisk's Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance

Caremark negotiated an undisclosed lower net price for Wegovy over Zepbound on its standard formularies, offering savings on Novo ... by requesting exemptions, JPMorgan analyst Chris Schott ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results